您的位置: 首页 > 农业专利 > 详情页

ENDONUCLEASE TARGETING BLOOD COAGULATION FACTOR VIII GENE AND COMPOSITION FOR TREATING HEMOPHILIA COMPRISING SAME
专利权人:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY;INSTITUTE FOR BASIC SCIENCE
发明人:
Dong Wook KIM,Jin Soo KIM,Chul Yong PARK,Duk Hyoung KIM,Jung Eun KIM,Jiyeon KWEON
申请号:
US15807844
公开号:
US20180071405A1
申请日:
2017.11.09
申请国别(地区):
US
年份:
2018
代理人:
摘要:
The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充